Brief: Wuxi Biologics (Cayman) Says Revenue Expected To Increase 16%, Profit Up 54% For HY
July 24 (Reuters) - WuXi Biologics (Cayman) Inc 2269.HK: REVENUE EXPECTED TO INCREASE 16%, PROFIT UP 54% FOR HY INCREASE DUE TO STRATEGIES AND TECHNOLOGY PLATFORMS IN HY Further company coverage: 2269.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on WuXi Biologics (Cayman)
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
WuXi Biologics H1 net profit up on margin expansion
Brief: WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln